Timber Pharmaceuticals (NYSE:TMBR – Get Rating) is one of 942 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Timber Pharmaceuticals to related companies based on the strength of its analyst recommendations, profitability, earnings, dividends, institutional ownership, valuation and risk.
Valuation & Earnings
This table compares Timber Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Timber Pharmaceuticals||$890,000.00||-$10.64 million||-1.10|
|Timber Pharmaceuticals Competitors||$1.86 billion||$250.59 million||-2.61|
This is a summary of current ratings and target prices for Timber Pharmaceuticals and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Timber Pharmaceuticals Competitors||2591||12276||38410||606||2.69|
Timber Pharmaceuticals currently has a consensus price target of $1.50, suggesting a potential upside of 426.32%. As a group, “Pharmaceutical preparations” companies have a potential upside of 133.39%. Given Timber Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Timber Pharmaceuticals is more favorable than its peers.
Institutional and Insider Ownership
19.8% of Timber Pharmaceuticals shares are held by institutional investors. Comparatively, 45.2% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 1.1% of Timber Pharmaceuticals shares are held by company insiders. Comparatively, 15.0% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Timber Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Timber Pharmaceuticals’ peers have a beta of 1.14, indicating that their average share price is 14% more volatile than the S&P 500.
This table compares Timber Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Timber Pharmaceuticals Competitors||-3,136.96%||-1,455.34%||-9.04%|
Timber Pharmaceuticals peers beat Timber Pharmaceuticals on 7 of the 13 factors compared.
Timber Pharmaceuticals Company Profile (Get Rating)
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.
Receive News & Ratings for Timber Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Timber Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.